Experience of large-scale AMH screening within the “Becoming a Mother” project in Moscow: integrating ovarian reserve testing into outpatient practice

Abstract

Declining birth rates in large cities and delayed motherhood require innovative approaches to maintaining the population’s reproductive health. The “Becoming a Mother” project (Moscow, 2024–2025) provides a unique experience of integrating anti-Müllerian hormone (AMH) screening into outpatient obstetrics and gynecology care. Objective. To present the results of large-scale AMH screening and analyze its clinical significance in the context of current data on the epidemiology of AMH level trends and strategies for preserving reproductive health. Materials and methods. A systematic review of literature for the period from 2020 to 2025 was conducted, along with an analysis of data from the “Becoming a Mother” project, in which 254,948 women who underwent AMH testing between September 9, 2024, and August 31, 2025, participated. Results. Distribution of results: AMH <1.2 ng/mL was observed in 19.5% of study participants; AMH 1.2–1.49 in 6.3%; and AMH ≥1.5 in 74.2%. Among women with AMH >20 ng/mL, polycystic ovary syndrome was diagnosed in 44.3% of cases, allowing timely initiation of treatment. A total of 11,071 women were referred to a gynecologist, and 658 women underwent oocyte cryopreservation (849 oocytes and 197 embryos were vitrified). The program demonstrated high efficacy in the timely detection of diseases and provided access to advanced reproductive technologies. Conclusion. The Moscow project represents an innovative experience in integrating ovarian reserve assessment into primary health care. The scale of the program and the data obtained contribute significantly to understanding the population-level epidemiology of reproductive health and open up prospects to improve medical care for reproductive-aged women. Key words: anti-Müllerian hormone, ovarian reserve, reproductive health, fertility preservation, preventive medicine, population policy